EuropaBio statement on court ruling that impacts genome-edited products
EuropaBio calls for change, following court ruling that impacts genome-edited products.
The European biotechnology industry warns that the recent EU court ruling impacting many products made with genome editing could cause European life science innovation to effectively come to a halt.
This would hinder EU sustainability and competitiveness ambitions, from the delivery of innovative bio-based products to sustainable food and certain healthcare solutions.
EuropaBio calls for science-based, predictable and proportionate rules, instead of disproportionate regulatory requirements, when the very same products could also be obtained through earlier breeding or classical mutagenesis methods or could simply result from spontaneous processes in nature.
Access the full statement here.
This content is published by the Parliament Magazine on behalf of our partners.
It is imperative to seize the momentum of recent policy developments at both European and international level, argues Philippe Mengal.
Europe is lagging behind on several breakthrough technologies, especially in the field of agricultural biotechnology, explains Joanna Dupont-Inglis.
Europe can compete at the highest levels of the bioeconomy, says Philippe Mengal.